Santos Esteban 4
4 · AMGEN INC · Filed Feb 21, 2025
Insider Transaction Report
Form 4
AMGEN INCAMGN
Santos Esteban
EVP, Operations
Transactions
- Exercise/Conversion
Nqso (Right to Buy)
2025-02-19−8,711→ 0 totalExercise: $156.35From: 2018-05-03Exp: 2026-05-03→ Common Stock (8,711 underlying) - Sale
Common Stock
2025-02-19$292.84/sh−8,711$2,550,903→ 71,546 total - Exercise/Conversion
Common Stock
2025-02-19$156.35/sh+8,711$1,361,965→ 80,257 total
Holdings
- 868.873(indirect: By 401(k))
Common Stock
Footnotes (4)
- [F1]These shares were acquired in connection with the exercise of stock options expiring on May 3, 2026.
- [F2]The price reported is an average price. The prices ranged from $292.7523 to $293.00 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.
- [F3]These shares include 667 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
- [F4]These shares are acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.